ImmunoGen Value Stock - Dividend - Research Selection
Market price: 6,40 USD
ImmunoGen Fundamental data and company key figures of the share
|Annual reports in USD|
|Net operating cash flow||-78.620.000|
|Free cash flow||-79.537.000|
|Liabilities & Shareholders equity||355.072.000|
|Diluted shares outstanding||194.710.000|
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
How our site works ...
✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe
Price for monthly subscription $ 19.99 / month including VAT.
|Market Capitalization||1.187.730.944,00 USD|
|Raw Data Source||US GAAP in Millionen USD|
Description of the company
ImmunoGen, Inc. (ImmunoGen) develops targeted, antibody-based therapeutics for the treatment of cancer. ImmunoGen designs linkers that enable antibody-based therapeutics for the treatment of cancer agents to remain stably attached to the antibodies while in the blood stream and be released in their fully active form after delivery to a cancer cell. An anticancer compound made using the Company´s Targeted Antibody Payload (TAP), technology consists of a monoclonal antibody. The CompanyÂ´s TAP technology is designed to enable the creation of well-tolerated anticancer products. As of June 30, 2012, ImmunoGen had three wholly owned clinical-stage product candidates included IMGN901, IMGN853, and IMGN529, and other TAP compounds in earlier stages of development.